140. ドラベ症候群 Dorabe syndrome Clinical trials / Disease details

臨床試験数 : 104 / 薬物数 : 61 - (DrugBank : 14) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 63

20 trials found

diseases per page:

Showing 1 to 10 of 20 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05044819 (ClinicalTrials.gov)	July 7, 2021	30/8/2021	Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol ...	A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated Wi ...	Lennox Gastaut Syndrome;Dravet Syndrome;Tuberous Sclerosis Complex	Drug: Cannabidiol	GW Research Ltd	NULL	Recruiting	1 Year	N/A	All	150	Phase 4	United States
2	NCT04611438 (ClinicalTrials.gov)	March 30, 2020	16/9/2019	Research on Cognitive Effect of Cannabidiolon Dravet Syndrome and Lennox-Gastaut SyndromeGastaut Syn ...	A Prospective Multi-Center Single-Arm Clinical Trial on Cognitive Effect of Cannabidiol(CBD-OS®) on ...	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: Cannabidiol	Yonsei University	NULL	Recruiting	2 Years	18 Years	All	107	Phase 3	Korea, Republic of
3	NCT03467113 (ClinicalTrials.gov)	January 19, 2018	30/1/2018	A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Synd ...	An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Comb ...	Dravet Syndrome;Lennox Gastaut Syndrome	Drug: ZX008 0.2 to 0.8 mg/kg/day;Drug: Cannabidiol	Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.	NULL	Completed	2 Years	18 Years	All	9	Phase 1/Phase 2	United States
4	NCT02318563 (ClinicalTrials.gov)	December 30, 2017	12/12/2014	CannabidiolOral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Co ...	A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Saf ...	Dravet Syndrome	Drug: Cannabidiol Oral Solution;Drug: Placebo Solution	INSYS Therapeutics Inc	NULL	Withdrawn	1 Year	30 Years	All	0	Phase 3	NULL
5	NCT02815540 (ClinicalTrials.gov)	February 16, 2017	20/6/2016	The Effects of Cannabidiol(CBD) on Electrical and Autonomic Cardiac Function in Children With Severe ...	The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children	Lennox-Gastaut Syndrome;Dravet Syndrome	Procedure: 12-Lead ECG;Drug: Cannabidiol	Gillette Children's Specialty Healthcare	NULL	Terminated	2 Years	30 Years	All	2	Phase 1/Phase 2	United States
6	EUCTR2014-001834-27-NL (EUCTR)	09/09/2015	18/06/2015	An open label study of the safety of cannabidiol(GWP42003-P) in children and adults with Dravet or L ...	An open label extension study to investigate the safety of cannabidiol(GWP42003-P; CBD) in children ...	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification ...	Trade Name: CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product N ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 3	United States;France;Spain;Poland;Australia;Israel;Netherlands;United Kingdom
7	EUCTR2014-001834-27-FR (EUCTR)	03/09/2015	20/07/2015	An open label study of the safety of cannabidiol(GWP42003-P) in children and adults with Dravet or L ...	An open label extension study to investigate the safety of cannabidiol(GWP42003-P; CBD) in children ...	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 18.0;Level: PT;Classification ...	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	530	Phase 3	United States;France;Spain;Poland;Israel;Netherlands;United Kingdom
8	EUCTR2014-001834-27-PL (EUCTR)	18/08/2015	14/05/2015	An open label study of the safety of cannabidiol(GWP42003-P) in children and adults with Dravet or L ...	An open label extension study to investigate the safety of cannabidiol(GWP42003-P; CBD) in children ...	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 20.0;Level: PT;Classification ...	Trade Name: CBD - Oral Solution, is known as Epidiolex, and is the approved name in the USA. Product N ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	680	Phase 3	United States;France;Spain;Poland;Australia;Israel;Netherlands;United Kingdom
9	NCT02224573 (ClinicalTrials.gov)	June 2015	21/8/2014	GWPCARE5 - An Open Label Extension Study of Cannabidiol(GWP42003-P) in Children and Young Adults Wit ...	An Open Label Extension Study to Investigate the Safety of Cannabidiol(GWP42003-P; CBD) in Children ...	Epilepsy;Dravet Syndrome;Lennox-Gastaut Syndrome	Drug: GWP42003-P	GW Research Ltd	NULL	Completed	2 Years	N/A	All	681	Phase 3	NULL
10	EUCTR2014-001834-27-ES (EUCTR)	21/05/2015	14/04/2015	An open label study of the safety of cannabidiol(GWP42003-P) in children and adults with Dravet or L ...	An open label extension study to investigate the safety of cannabidiol(GWP42003-P; CBD) in children ...	Dravet Syndrome (DS) or Lennox-Gastaut Syndrome (LGS) MedDRA version: 18.0;Level: PT;Classification ...	Product Name: Cannabidiol (CBD) Product Code: GWP42003-P INN or Proposed INN: N/A Other descriptive name ...	GW Research Ltd	NULL	Not Recruiting			Female: yes Male: yes	430	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France;United States;Poland;Spain;Israel;Netherlands;United Kingdom

First Previous1 2Next Last